Spire Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Spire Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,000	Closed	-$268K	–	2198
2022 Q2	$268K	Buy	7,000 +1,000	+17%	+$31.6K	0.01%	667
2022 Q1	$248K	Hold	6,000	–	–	0.01%	797
2021 Q4	$227K	Hold	6,000	–	–	0.01%	1041
2021 Q3	$198K	Buy	6,000 +5,000	+500%	+$195K	0.01%	932
2021 Q2	$67K	Hold	1,000	–	–	﹤0.01%	1355
2021 Q1	$57K	Buy	+1,000	New	+$70.3K	﹤0.01%	1656

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Spire Wealth Management's AXSM Position: Q3 2022 in Review

Spire Wealth Management sold out of Axsome Therapeutics (AXSM) in Q3 2022, closing a stake of 7,000 shares — an estimated $268K sold.

Spire Wealth Management first reported a position in AXSM in Q1 2021 and held it in 6 quarters. The position peaked at $268K in Q2 2022. 187 funds tracked by Wall St. Rank hold AXSM as of Q3 2022.

Spire Wealth Management reported no remaining Axsome Therapeutics position as of Q3 2022 after selling out during the quarter.
Spire Wealth Management sold 7,000 Axsome Therapeutics shares in Q3 2022, an estimated $268K.
Spire Wealth Management first reported a position in Axsome Therapeutics in Q1 2021 and held it in 6 quarters.
Spire Wealth Management's Axsome Therapeutics position peaked at $268K in Q2 2022.
187 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.